<sup>68</sup>Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial.

By contrast, the ΔSLD of CT scan ( P = 0.28) and ΔSUV max of 18 F-FDG ( P = 0.13) showed a tendency to differ between these two groups, but these differences did not reach statistical significance (Fig. 3c, d ).

also in 111,027 other papers

Patients assessed as the responders (partial metabolic response [PMR] and complete metabolic response [CMR]) using PERCIST/Lugano showed a trend towards improved PFS but no significant differences were observed ( P = 0.11; hazard ratio, 2.2; 95% CI, 0.8–6.6; Fig. 4f ).

also in 53,322 other papers